Press Releases

Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) held its annual general meeting on the 27th of October 2023. At the general meeting, the following resolutions were made.

Major shareholder acquires PHI’s convertible loan from Formue Nord

PHI informs the market that PHI’s largest investor, Altium S.A., has on this day taken over PHI’s outstanding convertible loan from Formue Nord.

PHI’s Board of Directors proposes signing Altium as global distributor partner

PHI’s Board of Directors decided to propose signing Altium S.A., which also is the Company’s largest shareholder, as a global PHI distributor partner.

PHI’s Board of Directors proposes a Direct Issue of shares of 9.9 MSEK to Altium

PHI’s Board of Directors proposes a direct issue of 2 374 820 new shares to the Company’s largest shareholder, Altium S.A.
Wake-Forest-North-Carolina

PHI endorses WFIRM as Finalist for NSF’s $160 Million Innovation Grant

PHI proudly stands behind the Wake Forest Institute for Regenerative Medicine (WFIRM) as they contend as a finalist in the National Science Foundation’s (NSF) Regional Innovation Engines competition, with a potential award of up to $160 million.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB

The shareholders of Phase Holographic Imaging PHI AB (publ), 556542-7811, are hereby invited to the annual general meeting on Friday 27 October 2023 at 13.00 at Scandic Star Hotel, Glimmervägen 5 in Lund.

Notice that Interim Report 1 2023/24 will be published on September 20, 2023

Phase Holographic Imaging announces that the date for publication of Interim Report 1 2023/24 is September 20, 2023.

PHI AB annual general meeting moved to 27 October 2023

The PHI AB board has decided to move the company’s annual general meeting from 12 October 2023 to 27 October 2023.
ARM-ATMP-banner-web

PHI Strengthens Commitment to Regenerative Medicine through ARM and ATMP Sweden Membership

PHI becomes a member of the leading international advocacy organization Alliance for Regenerative Medicine (ARM) as well as the national ATMP Sweden network to advocate for QPI technology for standard cell quality control in regenerative medicine.
Artistic image of molecularly imprinted polymers (MIP).

European Patent Office intends to grant PHI patent on synthetic antibodies

PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
123414